Somatropin biosimilar - Biopartners/LG Life Sciences

Drug Profile

Somatropin biosimilar - Biopartners/LG Life Sciences

Alternative Names: Declage; Eutrophine; Eutropin; Eutropin Plus; LB-03002; rhGH; Somatropin BioPartners; SR-rhGH; Valtropin

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator LG Life Sciences
  • Developer Biopartners GmbH; LG Life Sciences; Merck KGaA
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency
  • Phase III Prader-Willi syndrome

Most Recent Events

  • 19 May 2017 LG Life Sciences plans a phase I trial for different eutropin formulations in healthy volunteers (SC) (NCT03154840)
  • 01 Apr 2017 Adverse events, pharmacodynamics and efficacy data from a phase II trial in Short stature presented at The 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 04 Jun 2015 Somatropin biosimilar controlled release is still in phase III development for Somatotropin deficiency in adults and paediatric patients worldwide (including USA)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top